AbbVie
Search results
Innovating to solve some of today’s toughest medical challenges. Using key discoveries in the field of liver health, we’re advancing treatments for rare and serious liver diseases. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH ...
Our executive leadership taps into an expertise in liver health and strong business acumen. SEE WHO’S WHO. Vivek Devaraj, President – U.S. and Chairman.
Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases, with a focus on those with high unmet need. We are leveraging our decades of research and background in bile acids and FXR agonism to expand our pipeline to deliver effective treatments for the growing number of ...
Jan 19, 2023 · Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary...
Jun 22, 2023 · Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis...
Dec 20, 2021 · Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary...
Jun 23, 2023 · The FDA turned down an Intercept Pharmaceuticals drug application for the fatty liver disease NASH, a decision that comes nearly three years after the regulator first rejected the...
Sep 26, 2023 · Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price.
Nov 8, 2023 · Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.
